ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer.

Weng, Siyuan; Liu, Zaoqu; Xu, Hui; Ge, Xiaoyong; Ren, Yuqing; Dang, Qin; Liu, Long; Zhang, Jian; Luo, Peng; Ren, Jianzhuang; Han, Xinwei

Weng, Siyuan; Liu, Zaoqu; Xu, Hui; Ge, Xiaoyong; Ren, Yuqing; Dang, Qin; Liu, Long; Zhang, Jian; Luo, Peng; Ren, Jianzhuang; Han, Xinwei.

Afiliação

Weng S; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liu Z; Interventional Institute of Zhengzhou University, Zhengzhou, China.
Xu H; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Ge X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ren Y; Interventional Institute of Zhengzhou University, Zhengzhou, China.
Dang Q; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Liu L; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang J; Interventional Institute of Zhengzhou University, Zhengzhou, China.
Luo P; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Ren J; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Han X; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Front Immunol ; 13: 910582, 2022.

Article em En | MEDLINE | ID: mdl-35833141

Assuntos

Araquidonato 12-Lipoxigenase; Bevacizumab; Neoplasias Colorretais; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Araquidonato 12-Lipoxigenase/genética; Araquidonato 12-Lipoxigenase/metabolismo; Bevacizumab/uso terapêutico; Biomarcadores Tumorais/genética; Biomarcadores Tumorais/metabolismo; Neoplasias Colorretais/tratamento farmacológico; Neoplasias Colorretais/genética; Neoplasias Colorretais/metabolismo; Variações do Número de Cópias de DNA; Humanos; Imunoterapia; Prognóstico

Palavras-chave

ALOX12; bevacizumab; biomarker; colorectal cancer; immunotherapy; multi-omics; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google